succinic acid mono-[5-(4-tert-butoxycarbonylamino-2-oxo-2H-pyrimidin-1-yl)-3-hydroxymethyl-tetrahydro-furan-2-yl-methyl] ester | 918872-94-3

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: succinic acid mono-[5-(4-tert-butoxycarbonylamino-2-oxo-2H-pyrimidin-1-yl)-3-hydroxymethyl-tetrahydro-furan-2-yl-methyl] ester
• 英文别名: 4-[[(2S,3R,5R)-3-(hydroxymethyl)-5-[4-[(2-methylpropan-2-yl)oxycarbonylamino]-2-oxopyrimidin-1-yl]oxolan-2-yl]methoxy]-4-oxobutanoic acid
• CAS: 918872-94-3
• 化学式: C₁₉H₂₇N₃O₉
• 分子量: 441.438
• InChiKey: VKHVKBWCELCNFC-YRGRVCCFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  31
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  164
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  succinic acid mono-[5-(4-tert-butoxycarbonylamino-2-oxo-2H-pyrimidin-1-yl)-3-hydroxymethyl-tetrahydro-furan-2-yl-methyl] ester 在 N,N-二甲基甲酰胺 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 48.0h， 以31%的产率得到[1-(6,9-dioxo-decahydro-1,5,10-trioxa-cyclopentacyclodecen-2-yl)-2-oxo-1,2-dihydro-pyrimidin-4-yl]-carbamic acid tert-butyl ester
  参考文献：
  名称：

  WO2007/6707

  摘要：

  公开号：
• 作为产物：
  描述：

  succinic acid mono-{5-(4-tert-butoxycarbonylamino-2-oxo-2H-pyrimidin-1-yl)-3-[(4-methoxy-phenyl)-diphenyl-methoxymethyl]-tetrahydro-furan-2-yl-methyl} ester 在 溶剂黄146 作用下， 以 水 为溶剂， 反应 3.0h， 以73%的产率得到succinic acid mono-[5-(4-tert-butoxycarbonylamino-2-oxo-2H-pyrimidin-1-yl)-3-hydroxymethyl-tetrahydro-furan-2-yl-methyl] ester
  参考文献：
  名称：

  WO2007/6707

  摘要：

  公开号：

文献信息

• 1-[2', 3' -DIDEOXY-3' C- (HYDROXYMETHYL) - BETA-D-ERYTHRO-PENTOFURANOSYL] CYTOSINE DERIVATIVES AS HIV INHIBITORS
  申请人：ZHOU Xiao-Xiong

  公开号：US20110112294A1

  公开（公告）日：2011-05-12

  Compounds of the formula I wherein: R 1 is independently H, —OR 3 , —NHR 4 ; C 1 -C 4 alkyl; or, when n is 2, adjacent R 1 together define an olefinic bond; R 2 is H; or when the gem R 1 is C 1 -C 4 alkyl, that R 2 may also be C 1 -C 4 alkyl; or when the gem R 1 is —OR 3 , that R 2 may also be —C(═O)OH or a pharmaceutically acceptable ester thereof; R 3 is independently H, or a pharmaceutically acceptable ester thereof; R 4 is independently H or a pharmaceutically acceptable amide thereof; R 5 and R6 are H or an amine prodrug moiety n is 1, 2 or 3; and pharmaceutically acceptable salts thereof; have utility in the treatment or prophylaxis of HIV, especially reverse transcriptase mutants which allow an obligate chain terminating nucleoside- or nucleotide phosphate to be excised from the nascent DNA strand by ATP- or pyrophosphate-mediated excision.

  化合物的公式为I，其中： R1独立地为H、—OR3、—NHR4；C1-C4烷基；或当n为2时，相邻的R1共同定义一个烯烃键； R2为H；或当gem R1为C1-C4烷基时，R2也可以是C1-C4烷基；或当gem R1为—OR3时，R2也可以是—C(═O)OH或其药学上可接受的酯； R3独立地为H或其药学上可接受的酯； R4独立地为H或其药学上可接受的酰胺； R5和R6为H或一种胺前药物基团； n为1、2或3； 以及其药学上可接受的盐； 在治疗或预防HIV方面有用，特别是逆转录酶突变体，其允许ATP或焦磷酸介导的切除将一个必需的链终止核苷酸或核苷酸磷酸从新生DNA链中切除。
• 1-[2',3'-dideoxy-3'c-(hydroxymethyl)- beta-d-erythro-pentofuranosyl]cytosine derivatives as HIV inhibitors
  申请人：Medivir AB

  公开号：EP2336135A2

  公开（公告）日：2011-06-22

  A compound of the formula: for use in the treatment of retroviruses such as HIV, especially drug escape mutations.

  式中的化合物： 用于治疗逆转录病毒（如 HIV），尤其是药物逃逸突变。
• 1- [2' , 3' -DIDEOXY-3' C- (HYDROXYMETHYL) - BETA-D-ERYTHRO-PENTOFURANOSYL] CYTOSINE DERIVATIVES AS HIV INHIBITORS
  申请人：MEDIVIR AB

  公开号：EP1899352B1

  公开（公告）日：2011-10-05
• 1-[2',3' -Dideoxy-3' C-(Hydroxymethyl) - Beta-D-Erythro-Pentofuranosyl] Cytosine Derivatives as Hiv
  申请人：Zhou Xiao-Xiong

  公开号：US20080221140A1

  公开（公告）日：2008-09-11

  Compounds of the formula (I) wherein: R 1 is independently H 1 —OR 3 , —NHR 4 ; C 1 -C 4 alkyl; or, when n is 2, adjacent R 1 together define an olefinic bond; R 2 is H; or when the gem R 1 is C 1 -C 4 alkyl, that R 2 may also be C 1 -C 4 alkyl; or when the gem R 1 is —OR 3 , that R 2 may also be —C(═O)OH or a pharmaceutically acceptable ester thereof; R 3 is independently H, or a pharmaceutically acceptable ester thereof; R 4 is independently H or a pharmaceutically acceptable amide thereof; R 5 and R6 are H or an amine prodrug moiety n is 1, 2 or 3; and pharmaceutically acceptable salts thereof; have utility in the treatment or prophylaxis of HIV, especially reverse transcriptase mutants which allow an obligate chain terminating nucleoside- or nucleotide phosphate to be excised from the nascent DNA strand by ATP- or pyrophosphate-mediated excision.
• US7888367B2
  申请人：——

  公开号：US7888367B2

  公开（公告）日：2011-02-15